NanoM Wafer Ocular Insert: Innovative Eye Care Solution
Integral BioSystems has developed NanoM Wafer™, a bioengineered ocular insert, as a platform technology and patented them in global jurisdictions. We invite collaborations with pharmaceutical companies to render repurposed drugs IP-protectable with Integral’s proprietary drug delivery licensable innovation NanoM Wafer™. With multiple billion-dollar drug products going off-patent, a 505(b)(2) regulatory strategy presents a cost-effective way to develop an extended product life cycle with novel IP. Contact us for a discussion.
Benefits of Ocular Inserts Compared to Eye-drops
| Attributes | Eyedrops | Ocular Insert |
| Efficiency of absorption | Low absorption; losses due to lacrimal drainage | Higher efficiency—residence time on eye driven by residence time of polymers in insert |
| Bioavailability | Low, due to losses | Bioavailability can be enhanced by longer residence time afforded by dissolving inserts |
| Preservative | Preservative-free requires specialty CC | No preservative required |
| Stability | Formulation composition dependent | Stability is greatly enhanced due to dry physical state |
| Flexibility of dosing | Higher drug concentrations can be limited by drug solubility | Higher doses feasible in inserts |
| Combination drugs | Drugs combined in solution may be incompatible chemically | Co-incorporation of incompatible drugs |
| Self-Administered | Yes | Yes |
| Manufacturing | Established Technology | IP-dependent, but manufacturable |
| Packaging | LDPE eye-dropper | Peel-pouch, applicator |
| Sustained release | Low, or none | Highly versatile; ocular inserts can be designed to modulate release |
NanoM Wafer™: A Bioengineered Ocular Insert
- Dimensions : fits comfortably under lower eyelid
- Placement: placed in lower conjunctival fornix
- Turns into a translucent hydrogel upon hydration
- Fluids permeable (O2, CO2, H2O)
- >90% H2O
- Biodegradable
Value Proposition
Intellectual Property
- Family of patents in 12 global jurisdictions
- Platform technology
- IP covers both dissolvable and non-dissolvable wafers
- IP covers sustained release of drugs
- IP covers wafers with, and without drugs
Dissolvable Wafer: Applications in Ophthalmology
- Dry Eye
- Allergic Conjunctivitis
- Prevention of Inflammation post-cataract surgery
- Redness Reduction
- Ocular Pain
Removable Wafer for Sustained Release: Applications in Ophthalmology
- Sustained delivery for ocular disorders
Wafer Applications (Other Routes)
- Women’s Health
- Urologic
- Sinusoidal
- Sublingual
- Dermal
Dissolution Time of Dissolvable Wafer Can Be Modulated by Composition
The intricate fenestrations of the NanoM Wafer™ offer high contact with mucosal tissue, establishing mucoadhesive bonds.
- Rapid hydration
- “sinks” into tissue, while dissolving
NanoM Wafer™ Patent Granted in Global Jurisdictions
Platform Delivery System: w/ and w/o API, intercalation of neutral and mucoadhesive fibers formed by electrospinning, thickness 1-1000 nm, flexural modulus < 30 MPa
- NanoM Wafer trademark filed and in-use
- Fully Patented; patent life until 2035
- Wholly owned by Symphony parent company, Integral BioSystems
- Broad IP scope
- Both Composition and Process IP
- Patented in USA, Canada, Great Britain, France, Italy, Germany, Spain, India, Singapore, China, Japan, Australia, New Zealand, South Africa
- Additional evolving IP filed